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Abstract: The development of neuronal death and amyloid plaques is a characteristic feature 
of ischemic- and Alzheimer-type dementia. An important aspect of neuronal loss and amyloid 
plaques are their topography and neuropathogenesis. This review was performed to present the 
hypothesis that different fragments of blood-borne amyloid precursor protein are able to enter the 
ischemic blood–brain barrier. Chronic disruption of the blood–brain barrier after ischemic injury 
was shown. As an effect of chronic ischemic blood–brain barrier injury, a visible connection 
of amyloid plaques with neurovasculature was observed. This neuropathology appears to have 
similar distribution and mechanisms to Alzheimer’s disease. The usefulness of rival ischemic 
theory in elucidating the neuropathogenesis of amyloid plaques formation and neuronal death 
in Alzheimer’s disorder is discussed.
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Introduction
Two forms (genetic and sporadic) of Alzheimer’s disease involve main common events: 
neuronal damage and amyloid plaques accumulation in the human brain. Neuronal 
changes in the end-stage patient brain are diffuse and widespread and neuropathologi-
cal autopsy ﬁ  ndings include signiﬁ  cant neuron death. Moreover Alzheimer’s disease 
is characterized by a progressive dementia. An interesting suggestion about this 
phenomenon is that neuronal cells, which are involved with learning and memory, 
may synthesize speciﬁ  c substances associated with these cognitive activities and 
that dysfunction of the blood–brain barrier (Sohrabji 2007; Zipser et al 2007) may 
cause selective loss of these speciﬁ  c cells (Arshavsky 2006). The extracellular space 
in brain is inﬁ  ltrated by blood borne β-amyloid peptide 1–42, a neurotoxic peptide 
that interferes with the cells’ vital mechanisms and ultimately kills them (Atwood 
et al 2003a; Swerdlow 2007). This additional supporting evidence for blood–brain 
barrier disruption in Alzheimer’s disease, which is related to the accumulation of 
β-amyloid peptide; the featured lesion of the disorder (Pluta et al 1996). The brain 
vessels show signs of vessel inﬂ  ammation and amyloid depositions. Another set of 
evidence suggests that Alzheimer’s disease may have an autoimmune root, where 
especially neuronal cells are targeted after opening blood–brain barrier (D’Andrea 
2005). The ﬁ  rst description of the neuropathology in the patient brain suffering from 
Alzheimer’s disease by Alzheimer in 1907 presented cerebrovascular alterations of 
endothelium especially in small vessels (blood–brain barrier vessels) (Kalaria 1999, 
2002; Grammas 2000; Humpel and Marksteiner 2005; Dede et al 2007) that have not 
received much attention (Pluta 2000). The onset of Alzheimer’s disease is unknown 
and symptoms develop slowly during patient life. In the end stage of this disorder, Neuropsychiatric Disease and Treatment 2008:4(5) 856
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patients are totally dependent on caregivers and other diseases 
may lead them to death.
The etiology and important risk factors for Alzheimer’s 
disease are not well known (Spires and Hyman 2005; Pluta 
2006a). It is believed that major causes for this disorder 
include diseases of old age such as transient focal and com-
plete brain ischemic (Kalaria 2000; Pluta 2006a) and head 
(Nimmo et al 2004) injuries. Single and most probably mul-
tiple brain ischemic injuries can develop changes similar to 
those observed in Alzheimer’s disease (Pluta 2006a).
Some investigators have presented the hypothesis that the 
primary event in the onset of Alzheimer’s disease is ischemic 
injury of brain (Kalaria 2000; Pluta 2004b, 2006a). According 
to this rival theory the blood–brain barrier vessels are dam-
aged (Kalaria 1999; Dede et al 2007) and at the same time 
cause the neurotoxic β-amyloid peptide to be released from 
circulatory system into brain parenchyma (Pluta et al 1996) 
and subsequently react with ischemic neurons (Koistinaho 
et al 2002) as secondary cause of neuronal death (Figure 1).
The precursor protein for β-amyloid peptide can exist as 
both a membrane cell surface receptor and a soluble form, 
mostly in circulating blood. Blood platelets carry large 
amounts of β-amyloid peptide and its precursor (Chen et al 
1995). The prolonged opening of ischemic blood–brain bar-
rier to β-amyloid peptide (Pluta 2003, 2005; Pluta et al 2006) 
and exposure to the potentially neurotoxic peptide probably 
initiates amyloid plaques formation/maturation (Kawai et al 
1990; Dickstein et al 2006) with further additional neuronal 
cell death (Koistinaho et al 2002) and massive neuronal 
network destruction (Iwasaki et al 2006).
According to the ischemic theory of Alzheimer’s disease, 
neuronal cells are ﬁ  rst damaged and then the blood–brain 
barrier vessels are impaired, which causes the neurotoxic 
β-amyloid peptide to be released from blood and subse-
quently inﬁ  ltrate the neuronal cells and brain parenchyma 
(Pluta 2004a, 2004b, 2006a, 2006b, 2007a, 2007b). As a late 
effect, there will be a narrowing of the small vessels lumen 
leading to secondary ischemic brain episodes as a vicious 
cycle (Pluta 2006b, 2007b) in which the neuronal network 
will be completely impaired.
In this review we present data that supports the role of isch-
emia in neuronal death and ischemic blood–brain barrier in amy-
loid plaques development in Alzheimer’s disease etiology.
Inﬂ  uence of ischemia and β-amyloid 
peptide on brain cells
In the ischemic brain, the main neuropathological focus is 
concentrated on structural changes in hippocampus because 
this part of the brain is selectively vulnerable to ischemic- and 
Alzheimer-type injury. In some cases, complete disappear-
ance of vulnerable pyramidal neurons in the CA1 area was 
noted 7 days after ischemia (Butler et al 2002). Moreover, 
one third of cases with experimental brain ischemia did not 
present full disappearance of pyramidal cells in CA1 region 
during short-term survival (Sadowski et al 1999; Pluta 2000). 
These animals developed complete death of all neurons of 
CA1 sector in late stages (Pluta 2000, 2002a, 2002b). Some 
studies presented marked structural changes in neurons 
considered to be resistant to ischemia such as: in sector 
CA2, CA3, and CA4 of hippocampus and dentate gyrus 
(Pluta 2000). These areas presented acute ischemic changes 
in neurons from 1 to 12 months following ischemic injury 
(Pluta 2000). Recently was found that pathological structural 
processes in ischemic neurons continue well beyond the 
acute stages of insult (Pluta 2000, 2002a). In these situations, 
enduring ischemic blood–brain barrier dysfunction (Pluta 
2006b, 2007b) probably leads to enhanced ischemic neuro-
nal vulnerability to β-amyloid peptide (Figure 1) (Table 1) 
(Koistinaho et al 2002).
Some studies show that astrocytic apoptosis may contrib-
ute to the pathogenesis of different disorders such as ischemic 
brain and Alzheimer’s disease (Takuma et al 2004; Pluta 
2006a). Astrocytic reactions that are noted in the ischemic 
brain and Alzheimer’s disease are swelling, astrogliosis, 
and astrocytosis (Bernaudin et al 1998; Stoltzner et al 
2000). In brain ischemia, some experimental studies noted 
the early import of different epitopes of amyloid precursor 
protein from brain parenchyma and circulatory system to the 
astrocytes and in the late stages the export of the neurotoxic 
C-terminal of amyloid precursor protein and β-amyloid 
peptide from dead astrocytes to the brain tissue (Table 1) 
(Pluta et al 1994b; Pluta 2002b, 2004a, 2004b).
At early stages of brain ischemia and reperfusion, the 
N-terminal of amyloid precursor protein (Pluta et al 1994b) 
may be synthesized by cells derived from the vascular endo-
thelium that became fragmented after injury (Badan et al 
2004). This idea is supported by the expression and produc-
tion of β-secretase in ischemic brain (Wen et al 2004; Sun et al 
2006; Zhang et al 2007). Furthermore presenilin expressed 
in ischemic brain (Tanimukai et al 1998; Pennypacker et al 
1999; Pluta 2001) is involved in the metabolism of amyloid 
precursor protein to produce β-amyloid peptide through the 
γ-secretase complex (Wolfe et al 1999). These secretases are 
involved in amyloidogenic metabolism of amyloid precur-
sor protein. At ﬁ  rst, amyloid precursor protein is cleaved 
at the N-terminal of the β-amyloid peptide domain by Neuropsychiatric Disease and Treatment 2008:4(5) 857
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Figure 1 Schematic diagram of the main ischemic pathological processes in sporadic Alzheimer’s disease.
Abbreviations: APP, amyloid precursor protein; βA, β-amyloid peptide; BBB, blood–brain barrier.
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protease called β-secretase. In the second step, the product 
of β-secretase is cleaved by γ-secretase to form free soluble 
β-amyloid peptide. Endothelial cells change shape and size 
over time to become incorporated into the amyloid plaques in 
a close spatial relationship with damaged or dead astrocytes. 
The same study shows that C-terminal of amyloid precursor 
protein accumulates in neurons after focal ischemia and as 
the infarct progresses, the C-terminal of amyloid precursor 
protein immunoreactive elements become increasingly larger 
in the core even though the neurons are dying and the core 
becomes largely acellular (Badan et al 2004). The same and 
other studies suggest that C-terminal of amyloid precursor 
protein and β-amyloid peptide noted in microglia could be 
due to the phagocytosis of dead neurons remnants contain-
ing C-terminal of amyloid precursor protein and β-amyloid 
peptide by microglia (Figure 1) (Table 1) (Badan et al 2004; 
D’Andrea et al 2004). Moreover there are reports showing 
that astrocytes but not microglial cells can take up β-amyloid 
peptide (Table 1) (Matsunaga et al 2003; Wyss-Coray et al 
2003; Pluta 2006a). Other work shows that C-terminal of 
amyloid precursor protein induces the death of astrocytes 
whereas the loss of neurons is a secondary consequence of 
the neuronal dependence on astrocytes for antineurotoxic 
β-amyloid peptide protection (Figure 1) (Table 1) (Abramov 
et al 2003; Pluta 2006a). The localization of some fragments 
of amyloid precursor protein in astrocytes may be of sig-
niﬁ  cant relevance to Alzheimer’s disease in which chronic 
astrocytosis is thought to play a key role in the evolution of 
amyloid plaques.
Ischemic blood–brain barrier 
permeability
Brain ischemia mediated a number of vessel events which 
are open blood–brain barrier and tight junctions, diffuse 
leakage across necrotic vessel walls, and vasoconstriction 
(Petito et al 1982; Mossakowski et al 1993, 1994; Pluta et al 
1994a, 2006; Wisniewski et al 1995; Gartshore et al 1997; 
Shinnou et al 1998; Lippoldt et al 2000; Ueno et al 2002; 
Pluta 2003, 2005).
Until one year following brain ischemia-reperfusion 
injury brain gray and white matter areas contained single 
isolated and scattered sites of horseradish peroxidase extrava-
sations (Table 2) (Mossakowski et al 1994; Pluta et al 1994a, 
2006; Pluta 2003, 2005). Microscopic studies of different 
ischemic brain sections revealed diffuse and focal staining 
of tracer. Penetrating vessels across different brain structures 
displayed horseradish peroxidase immunoreactivity in walls. 
In hippocampus, cortex, basal ganglia, and thalamus and 
cerebellum, the above horseradish peroxidase leakage was 
noted. In summary, ischemic brains presented chronic and 
random blood–brain barrier changes. Horseradish peroxi-
dase permeability involved arterioles, capillaries, venules, 
and veins.
After short-term survival (7 days) following brain isch-
emia, experimental animals presented with gray and white 
matter perivascular immunoreactivity for all epitopes of 
amyloid precursor protein (Table 2) (Pluta et al 1994b). On 
the contrary, following long-term survival of animals, stain-
ing only for the toxic C-terminal of amyloid precursor protein 
and to the β-amyloid peptide was observed (Pluta et al 1997b; 
Pluta 2000, 2003, 2005). Multiple and abundant C-terminal 
of amyloid precursor protein and β-amyloid peptide stain-
ing deposits embraced and/or adjoined the capillaries. The 
deposits size was different and irregular in shape. Diffuse 
deposits of C-terminal of amyloid precursor protein and 
β-amyloid peptide like “puff of smoke” were also observed. 
Capillaries lumens and their inner and outer side of walls 
were also stained. Immunoreactivity inside capillaries with 
Table 1 Ischemia and β-amyloid peptide and brain cells
Cells Inﬂ  uence References
Neurons +++ Pluta et al 1994b, 1997b;   Abramov et al 2003; Badan et al 2004; Pluta 2006a
Astrocytes ++ Banati et al 1995; Palacios et al 1995; Pluta et al 1996, 1997b, 1999; Pluta 2000, 
2002a, 2002b, 2006a; Nihashi et al 2001; Matsunaga et al 2003;    Wyss-Coray et al 
2003; Koistinaho et al 2004; Takamura et al 2004
Oligodendrocytes ++ Irving et al 1997; Pluta et al 1997b; D’Andrea et al 2004
Microglial cells + Banati et al 1995; Badan et al 2004; Malm et al 2005; Pluta 2006a; Simard et al 2006
Ependymal cells +++ Pluta et al 1996, 1997a, 1997b
Endothelial cells +++ Pluta et al 1996, 1997a, 1997b;   Thomas et al 1996; Badan et al 2004
Pericytes ++ Pluta et al 1996; Lupo et al 2001;   Anfuso et al 2004
Notes: Inﬂ  uence, +++ – strong; ++ – moderate; + – weak.Neuropsychiatric Disease and Treatment 2008:4(5) 859
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a halo of C-terminal of amyloid precursor protein staining in 
the surrounding parenchyma (Pluta 2005) suggested diffusion 
of C-terminal of amyloid precursor and β-amyloid peptide 
out of the vascular compartment (Table 2). In any case, the 
halo of β-amyloid peptide staining in the perivascular space 
suggests that β-amyloid peptide can easy cross small vessel 
walls. These deposits were noted mainly in the hippocampus, 
brain, and entorhinal cortex.
The above suggestions are supported by intravenous 
injection of human β-amyloid peptide 1–42 into ischemic 
animals, which accumulated this peptide in the ischemic brain 
gray and white matter vessels walls and in perivascular space 
(Table 2) (Pluta et al 1996, 1997a, 1999). β-amyloid peptide 
1–42 can be transported by the blood–brain barrier receptor-
mediated transport (Deane et al 2003) and by blood–brain 
barrier permeability caused by ischemic injury (Pluta et al 
1996, 1997a, 1999, 2000) or β-amyloid neurotoxicity on 
ischemic blood–brain barrier structure (Table 1) (Thomas 
et al 1996; Fiala et al 1998; Farkas et al 2003; Paris et al 
2004a, 2004b).
The abnormal staining for apolipoproteins E, A1, and J 
was noted perivascularly (Table 2) (Kida et al 1995; Pluta 
2000). Apolipoprotein perivascular deposits were well 
delineated and irregular and with contact with ischemic 
blood–brain barrier vessels. Diffuse, broad, but faint areas 
were also seen. Extracellular apolipoproteins E and J deposits 
were heavily labeled by antibody to apolipoprotein A1, stron-
ger than by apolipoprotein E antibody (Kida et al 1995). They 
were stained stronger by antibody to apolipoprotein E than 
apolipoprotein J (Kida et al 1995). It is of interest to notice 
that perivascular deposits of apolipoproteins colocalize 
with deposits of different fragments of amyloid precursor 
protein (Kida et al 1995). Apolipoprotein E can modulate 
and promote the aggregation of soluble β-amyloid peptide 
into the ﬁ  brillar conformation. Apolipoprotein J is implicated 
in transport of β-amyloid peptide across the blood–brain 
barrier. The main role of apolipoproteins E, A1, and J in 
controlling the levels of soluble β-amyloid peptide in the 
extracellular/perivascular space of brain as well as their 
inﬂ  uence on amyloid plaques formation is suggested. These 
data demonstrate additive effects of apolipoproteins on inﬂ  u-
encing β-amyloid peptide deposition around blood vessels 
and that they play an important role in regulating extracel-
lular brain β-amyloid peptide metabolism independent of 
β-amyloid peptide synthesis. Another function, especially 
for apolipoprotein E in brain, is the suggested clearance of 
ischemic tissue probably by reverse transport of remnants 
into blood (Pluta et al 2000). Delayed clearance may ham-
per healing and reconstruction of the ischemic blood–brain 
barrier. These observations indicate that perivascular apo-
lipoproteins E, A1, and J accumulation after ischemia may 
represent a secondary injury factor that could exacerbate 
healing of ischemic brain.
In different times following ischemic brain injury plate-
lets occurring in aggregates were noted to adhere to the 
endothelium lining of ischemic blood–brain barrier vessels 
(Pluta et al 1994c; Pluta 2003, 2005). Ischemic platelets 
contained pseudopodia, which made strong contact with the 
endothelium. As an effect of these alterations the “no-reﬂ  ow 
phenomenon” was noted (Mossakowski et al 1993; Pluta et al 
Table 2 Ischemic blood–brain barrier permeability
Permeability Intensity References
HRP ↔ Petito et al 1982; Pluta et al 1994a, 2006; Gartshore et al 1997; Shinnou et al 1998; 
Ueno et al 2002; Pluta 2003, 2005; Gidday et al 2005
NAPP ↓ Pluta et al 1994b; Badan et al 2004; Pluta 2005
βA ↑ Pluta et al 1994b, 2006; Jendroska et al 1995; Ishimaru et al 1996;   Wisniewski 
and Maslinska 1996; Pluta 2003, 2005;   Van Groen et al 2005
CAPP ↑ Pluta et al 1994b, 2006; Pluta 2003, 2005; Badan et al 2004
βA1-42 ↑ Pluta et al 1996, 1997a, 1999, 2000
Apo E ↑ Kida et al 1995; Ishimaru et al 1996; Pluta 2000
Apo A1 ↑ Kida et al 1995; Pluta 2000
Apo J ↑ Kida et al 1995; Pluta 2000
Platelets ↑ Pluta et al 1994c; Ishikawa et al 2004; Ritter et al 2005
Leukocytes ↑ Caceres et al 1995; Farkas et al 2003; Ishikawa et al 2004; Ritter et al 2005; Pluta 2006a
Notes: Intensity, ↔ permanent; ↑ increasing; ↓ decreasing.
Abbreviations: HRP, horseradish peroxidase; NAPP, N-terminal of amyloid precursor protein; βA, β-amyloid peptide; CAPP, C-terminal of amyloid precursor protein; 
βA1–42, human β-amyloid peptide 1–42;   Apo E, apolipoprotein E;   Apo A1, apolipoprotein A1;  Apo J, apolipoprotein J.Neuropsychiatric Disease and Treatment 2008:4(5) 860
Pluta and Ułamek
1994c; Pluta 2003). Moreover, platelets were observed on 
the abluminal side of vessels (Table 2) (Pluta et al 1994c; 
Pluta 2003, 2005). These kind of changes occurred in 
arterioles, capillaries, venules, and veins independently of 
survival time following brain ischemia. Some data suggest 
that ischemic brain injury results in an increase number of 
platelet-leukocytes complexes (Ishikawa et al 2004) in the 
circulatory system (Ritter et al 2005). Another study pre-
sented increased platelet-leukocyte-endothelium interactions 
after local brain ischemia (Ishikawa et al 2004). A growing 
body of evidence has suggested that white cells can play an 
important pathological role in ischemic brain (Caceres et al 
1995; Gidday et al 2005). Matrix metalloproteinase-9 from 
white cells recruited to the ischemic brain tissue promotes 
further white cell recruitment (Table 2) to the same brain 
areas in a positive feedback manner and causes second-
ary blood–brain barrier breakdown to a primary ischemic 
episode (Gidday et al 2005). Microscopic investigation of 
ischemically damaged blood–brain barrier vessels identiﬁ  ed 
leukocytes adhering to the endothelium of capillaries and 
venules (Caceres et al 1995). This phenomenon is probably 
important in transendothelial leukocytes passage (Table 2). 
Endothelial changes and white cells accumulation and adher-
ence also reﬂ  ect a “no-reﬂ  ow phenomenon.”
Inﬂ  uence of β-amyloid peptide 
on ischemic blood–brain barrier
Studies of ischemic microvessels from brain presented 
vasospasm during recirculation time (Wisniewski et al 
1995; Ohtake et al 2004). The pathological hallmarks of 
vasospasm included undulations of basement membrane 
and endothelium with an increased number of endothelial 
microvilli (Pluta et al 1991). Some damaged endothelial 
cells presented rupture of endothelium membranes (Caceres 
et al 1995). Other studies of ischemic endothelium included 
an increased number of deep crater-like pits, endothelium 
microvilli, and enlarged junctional ridging (Pluta et al 1991). 
As an effect of presented pathology, aggregating platelets 
developed microthrombi attached to the vessel wall, which 
caused a continuous supply of constrictors such as β-amyloid 
peptide (Chen et al 1995; Thomas et al 1996). Current results 
suggest that platelets are the main ischemic cause in reper-
fusion injury, not only through aggregation and thrombus 
formation, but also through involvement in inﬂ  ammation 
processes with leukocytes (Nishijima et al 2004). Due to the 
fact that soluble β-amyloid peptide causes vascular constric-
tion (Thomas et al 1996; Niwa et al 2001) and endothelial 
cell injury (Table 1) (Thomas et al 1996), a role for soluble 
β-amyloid peptide in vasospasm and blood–brain barrier 
changes has been suggested. During recirculation following 
ischemic brain injury, islets of necrotic endothelium in 
capillaries was found (Petito et al 1982; Mossakowski et al 
1994; Pluta et al 1994a). Necrotic blood–brain barrier 
vessels characterize diffuse leakage of different blood ele-
ments (Petito et al 1982; Mossakowski et al 1994; Pluta 
et al 1994a). This phenomenon is probably due to senescent 
endothelium, which is triggered during reperfusion and is 
accelerated by β-amyloid peptide (Mossakowski et al 1994). 
Senescent endothelial cells are a common hallmark of vessel 
aging (Erusalimsky and Kurz 2005) and are probably also 
accelerated by ischemic insults (Mossakowski et al 1994). 
Another problem during recirculation, senescent endothelial 
cells are covered with β-amyloid peptide ischemic vessel 
walls where β-amyloid peptide acts as antiangiogenic factor 
(Paris et al 2004a, 2004b). Ischemic episodes and β-amyloid 
peptide harmful inﬂ  uence on pericytes (Table 1) (Lupo 
et al 2001; Anfuso et al 2004) and astrocytes (Table 1) can 
regulate blood–brain barrier vessel angiogenesis and can 
disrupt the normal blood–brain barrier function (Ramsauer 
et al 2002).
Guarding ischemic brain 
by estrogens
The incidence of Alzheimer’s disease cases is gender-
related (Pluta 2006a) and the risk of Alzheimer’s disease in 
women is signiﬁ  cantly greater than in men. The cumulative 
risk for Alzheimer’s disease in women is greater because 
of a lack of estrogen (Figure 2) after menopause, which 
has been proposed as a risk factor for Alzheimer’s disease 
among women (Pluta 2006a). Estrogen effects have been 
presented as blood–brain barrier function control through 
intercellular junction proteins (Kang et al 2006) and/or 
intracellular transport elements and through protective 
effects on the cellular components of barrier such as endo-
thelial, pericytes, and astrocytes cells (Yang et al 2005), 
cells which are vulnerable to aging and ischemia (Table 1) 
inﬂ  uence in the context of normal blood–brain barrier 
activity (Figure 2) (Sohrabji 2007; Zipser et al 2007). 
Pathological permeability of the blood–brain barrier can 
expose brain parenchyma to different elements of blood 
(Table 2) that directly and/or indirectly harm neuronal cells 
(Table 1) and potentate other neuropathological processes. 
Age-related cascades in different areas of the brain can have 
far reaching consequences for cognitive ability and affect. 
Most investigators have taken the approach of studying 
estrogen inﬂ  uence on neuropathological events related to Neuropsychiatric Disease and Treatment 2008:4(5) 861
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Alzheimer’s disease (Figure 2) (Simpkins et al 1997; Dubal 
et al 1998; Shi et al 1998; Chi et al 2002, 2005). Estrogens 
exert neuroprotective activity in experimental models of 
brain ischemia (Figure 2) (Simpkins et al 1997; Dubal et al 
1998; Shi et al 1998; Chen et al 2001; Chi et al 2002; Yang 
et al 2005), but the precise mechanism of their protection is 
not clearly understood. These hormones may preserve neu-
ronal health (Chen et al 2001) by maintaining the integrity 
of the blood–brain barrier (Figure 2) (Chi et al 2002, 2005). 
Another possibility is that estrogen attenuates overexpres-
sion of amyloid precursor protein messenger RNA (Shi et al 
1998). The protective effects of estrogens are seen in all 
of the neurovascular unit components including vascular 
endothelial cells, astrocytes, microglia, and neurons (Chen 
et al 2001; Yang et al 2005). Additionally postischemic 
estrogens reduce hypoperfusion and secondary ischemic 
episodes following brain ischemia (McCullough et al 2001). 
Prevention of brain ischemia and treatment ischemic epi-
sodes may have signiﬁ  cant implications for Alzheimer’s 
disease therapy. In view of the earlier observations that 
cognitive decline is progressing after brain ischemia, there 
is the distinct possibility that we can prevent this decline 
by targeting the slowly progressing pathology that follows 
ischemic injury by aiming at molecular events now shown 
to change following brain ischemia.
Conclusion
β-amyloid peptide is the main element of the ﬁ  brils in 
senile plaques in the Alzheimer’s disease brain. A soluble 
form of β-amyloid peptide has been found in plasma 
(Mehta and Pirttila 2002). A main vascular source for both 
the amyloid precursor protein and soluble β-amyloid peptide 
are in blood platelets. There is a growing body of evidence 
indicating that 90% of soluble β-amyloid peptide found 
in the circulatory system is stored in platelets body (Chen 
et al 1995). Acute and chronic ischemic neuronal death and 
ischemic neurons with enduring blood–brain barrier leak-
age (Pluta 2003, 2005; Pluta et al 2006) and platelets in the 
blood–brain barrier vessels’ perivascular space (Table 2) 
(Pluta et al 1994c; Pluta 2003) with neurotoxic epitopes of 
amyloid precursor protein deposition are involved in the 
gradual maturation of injurious process in ischemic gray and 
white matter (Table 1), which lead to progressive dementia 
and Alzheimer’s disease (Pluta 2007c).
We propose the role for brain ischemic injury as an 
alternative etiology/hypothesis of Alzheimer’s disease that 
triggers repetitive microischemic insults which form the 
basis for development of main neuropathological processes 
in Alzheimer’s disease (Pluta 2007c). The proﬁ  le of neu-
ronal and blood–brain barrier pathology noted in ischemic 
brain shares a commonality with the same alterations in 
Alzheimer’s disease. Ischemic neuronal changes have been 
implicated in the pathogenesis of dementia and ischemic 
blood–brain barrier changes are involved in amyloid plaques 
formation (Ujiie et al 2003). In Alzheimer’s disease, the 
decreased length of cerebral capillaries correlates well with 
neuropathology and clinical features of dementia (Attems and 
Jellinger 2004; Bailey et al 2004). Islets of regressed, senes-
cent (Minamino et al 2004) and degenerated ischemically 
blood–brain barrier vessels (Petito et al 1982; Mossakowski 
et al 1994; Pluta et al 1994a) probably act as seeds-core for 
the amyloid plaques. Thus, this data support theory that 
chronic ischemic blood–brain barrier permeability can cause 
angiopathy, vascular senescence (Minamino et al 2004), neu-
roinﬂ  ammatory response (Nimmo et al 2004), and amyloid 
plaques, which also occur in the Alzheimer’s disease brain.
The dysfunction of ischemic blood–brain barrier vessels 
with insufﬁ  cient repair (Atwood et al 2003b; Dickstein et al 
2006), vascular regression, and senescence, and aberrant 
and insufﬁ  cient angiogenesis represent new pathogenic 
mechanism(s) involved in maturation of Alzheimer’s dis-
ease and ﬁ  nal development of amyloid plaques which are 
unrelated to primary ischemic neuronal death (Ishimaru et al 
1996; Van Groen et al 2005).
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